{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T05:31:10Z","timestamp":1649050270126},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T00:00:00Z","timestamp":1468800000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00120-016-0178-2","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T09:37:53Z","timestamp":1468834673000},"page":"1164-1172","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medikament\u00f6se Therapie des\u00a0hormonsensitiven metastasierten Prostatakarzinoms"],"prefix":"10.1007","volume":"55","author":[{"given":"C.-H.","family":"Ohlmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,18]]},"reference":[{"key":"178_CR1","unstructured":"DKG\/AWMF (2014) Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms"},{"key":"178_CR2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467\u2013479","journal-title":"Eur. Urol."},{"key":"178_CR3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","volume":"61","author":"V Pagliarulo","year":"2012","unstructured":"Pagliarulo V, Bracarda S, Eisenberger MA et\u00a0al (2012) Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 61:11\u201325","journal-title":"Eur. Urol."},{"key":"178_CR4","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL et\u00a0al (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314\u20131325","journal-title":"N. Engl. J. Med."},{"key":"178_CR5","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","volume":"67","author":"ND James","year":"2015","unstructured":"James ND, Spears MR, Clarke NW et\u00a0al (2015) Survival with newly diagnosed metastatic prostate cancer in the \u201cDocetaxel era\u201d: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK\/06\/019). Eur Urol 67:1028\u20131038","journal-title":"Eur. Urol."},{"key":"178_CR6","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1200\/JCO.2007.15.9830","volume":"26","author":"RE Millikan","year":"2008","unstructured":"Millikan RE, Wen S, Pagliaro LC et\u00a0al (2008) Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J\u00a0Clin Oncol 26:5936\u20135942","journal-title":"J Clin Oncol"},{"key":"178_CR7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1442-2042.2004.t01-1-00748.x","volume":"11","author":"M Noguchi","year":"2004","unstructured":"Noguchi M, Noda S, Yoshida M et al (2004) Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103\u2013109","journal-title":"Int J Urol"},{"key":"178_CR8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10147-006-0563-8","volume":"11","author":"S Hoshi","year":"2006","unstructured":"Hoshi S, Yamaguchi O, Fujioka T et\u00a0al (2006) A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer. Int J Clin Oncol 11:303\u2013308","journal-title":"Int J Clin Oncol"},{"key":"178_CR9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14:149\u2013158","journal-title":"Lancet Oncol."},{"key":"178_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.11.005","author":"G Gravis","year":"2015","unstructured":"Gravis G, Boher JM, Joly F et al (2015) Androgen Deprivation Therapy (ADT) plus Docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. doi:10.1016\/j.eururo.2015.11.005","journal-title":"Eur. Urol."},{"issue":"5s","key":"178_CR11","doi-asserted-by":"crossref","first-page":"LBA2","DOI":"10.1200\/jco.2014.32.18_suppl.lba2","volume":"32","author":"C Sweeney","year":"2014","unstructured":"Sweeney C, Chen Y, Carducci MA et al (2014) Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J\u00a0Clin Oncol 32(5s):LBA2","journal-title":"J Clin Oncol"},{"key":"178_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1503747","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. doi:10.1056\/nejmoa1503747","journal-title":"N. Engl. J. Med."},{"key":"178_CR13","unstructured":"Patrick-Miller LJ et al (2016) Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805). J\u00a0Clin Oncol 34(Suppl):abstr 5004"},{"key":"178_CR14","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/jco.2015.33.3_suppl.395","volume":"33","author":"ND James","year":"2015","unstructured":"James ND, Sydes MR, Mason M et al (2015) Docetaxel and\/or zoledronic acid for hormone-na\u00efve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 33:5001","journal-title":"J Clin Oncol"},{"key":"178_CR15","volume-title":"ASCO Annual Meeting","author":"IF Tannock","year":"2015","unstructured":"Tannock IF, Amir E (2015) Clinical trial design and chemotherapy use in prostate cancer: correcting old mistakes, making new ones. discussant of abstr. 5001. In: ASCO Annual Meeting. J\u00a0Clin Oncol, Chicago"},{"key":"178_CR16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2015.09.013","volume":"69","author":"M Tucci","year":"2016","unstructured":"Tucci M, Bertaglia V, Vignani F et al (2016) Addition of Docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: A systematic review and meta-analysis. Eur Urol 69:563\u2013573","journal-title":"Eur. Urol."},{"key":"178_CR17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LH et al (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17:243\u2013256","journal-title":"Lancet Oncol."},{"key":"178_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.03.003","author":"A Ramos-Esquivel","year":"2016","unstructured":"Ramos-Esquivel A, Fern\u00e1ndez C, Zeled\u00f3n Z (2016) Androgen-deprivation therapy plus chemotherapy in metastatic hormone-sensitive prostate cancer. A systematic review and meta-analysis of randomized clinical trials. Urol Oncol. doi:10.1016\/j.urolonc.2016.03.003","journal-title":"Urol Oncol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-016-0178-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-016-0178-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-016-0178-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:38:11Z","timestamp":1498329491000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-016-0178-2"}},"subtitle":["Konsensuspapier AKO\/AUO"],"short-title":[],"issued":{"date-parts":[[2016,7,18]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["178"],"URL":"https:\/\/doi.org\/10.1007\/s00120-016-0178-2","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,18]]}}}